ERBB2 and breast carcinoma: The findings of the phase III OlympiAD trial (olaparib vs. chemotherapy median PFS of 7.0 vs. 4.2 months; hazard ratio = 0.58, 95% CI: 0.43–0.80) showed that patients with HER2‐negative locally advanced breast cancer or mBC and gBRCA1/2m derive significant benefit from PARPi therapy, which also applied to the phase III EMBRACA study (talazoparib vs. chemotherapy, median PFS of 8.6 vs. 5.6 months; hazard ratio = 0.54, 95% CI: 0.41–0.71) [128, 129].